Antitumor antibiotic bu-3983t
CA 2027601 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Sugawara, Koko; Nishiyama, Yuji; Yamamoto, Haruaki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel antitumor antibiotic, BU3983T, and a process for preparing same by culturing microorganisms belonging to the genus Actinomadura. This compound demonstrates a high level of antitumor activity against mouse B16 melanoma. An Actinomadura, Strain No. Q886-2, was isolated from a soil sample collected in Batangas, Luzon Island Philippines. The new antitumor antibiotic BU-3983T was obtained by fermentation of this strain. Based upon the morphology cultural and physiological characteristics and cell chemistry, the above-mentioned strain was identified as a species of Actinomadura, i.e. Actinomadura verrucosospora.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 15, 1990. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 15, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 15, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.